Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

被引：0
|
作者：
Yu, Evan Y.
Joshua, Anthony M.
Shore, Neal D.
Kramer, Gero
Hu, Haixia
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA USA
[2] St Vincents Hosp Sydney, Sydney, NSW, Australia
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Med Univ Vienna, Vienna, Austria
[5] Merck & Co Inc, Rahway, NJ USA
[6] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-180-5577-2829-12292; 613-615-646-3281-7408-2638; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-4809-5347; 261-566-9263; 283-183-143-3231-2482; 6; 5; 4; 3; 4082; 242; 256; 38092-25779; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS250
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS250 / TPS250
页数：1
相关论文
共 50 条
  • [31] KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
    Petrylak, Daniel P.
    Ratta, Raffaele
    Gafanov, Rustem
    Facchini, Gaetano
    Piulats, Josep M.
    Kramer, Gero
    Flaig, Thomas W.
    Chandana, Sreenivasa R.
    Li, Ben
    Burgents, Joseph
    Fizazi, Karim
    FUTURE ONCOLOGY, 2021, 17 (25) : 3291 - 3299
  • [32] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Keynote-199: Updated analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel
    Goh, Jeffrey C.
    Antonarakis, Emmanuel S.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    de Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian H.
    de Bono, Johann S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 48 - 49
  • [34] Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
    Antonarakis, Emmanuel S.
    Goh, Jeffrey C.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [35] PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
    Nordquist, Luke T.
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Massard, Christophe
    Stoeckle, Michael
    Carles, Joan
    Kolinsky, Michael Paul
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    de Bono, Johann S.
    JOURNAL OF UROLOGY, 2021, 206 : E417 - E417
  • [36] Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P.
    Todenhoefer, T.
    Laguerre, B.
    Arranz, J.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Huang, M.
    Li, Y.
    Qiu, P.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S387 - S387
  • [37] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine
    Lim, Emerson A.
    Petrylak, Daniel P.
    Peng, Weimin
    Kheoh, Thian
    Maul, Scott
    Smit, Johan W.
    Gonzalez, Martha D.
    De Porre, Peter
    NamPhuong Tran
    Nanus, David M.
    EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
  • [38] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Todenhofer, Tilman
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Byun, Seok-Soo
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345